zoledronic acid has been researched along with Osteoporotic Fractures in 92 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 51 (55.43) | 24.3611 |
| 2020's | 41 (44.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, S; Liu, K; Shi, X; Tang, B; Wu, L; Zeng, H | 1 |
| Body, JJ; Meier, C; Paccou, J; Palermo, A; Pepe, J; Tsourdi, E; Zillikens, MC | 1 |
| Feng, D; Ke, L; Liu, J; Luo, F; Mori, T; Wan, Y; You, R; Yu, G; Zhang, Y | 1 |
| Charokopou, M; Javaid, MK; Libanati, C; Pinedo-Villanueva, R; Willems, D; Yehoshua, A | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Chang, CW; Hsu, JC; Hwang, JS; Li, CC; Tai, TW; Wu, CH | 1 |
| Farooki, A; Lipitz-Snyderman, A; Meza, AM; Mitchell, AP; Morris, MJ; Panageas, KS | 1 |
| Liu, K; Lu, Q; Sun, W; Tan, G; Tang, J; Yu, D | 1 |
| Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
| Beyer, L; Bolster, MB; Cevallos, S; Espinoza, J; Fan, W; Finkelstein, JS; Garcia, EF; Kronenberg, HM; Leder, BZ; Machado, M | 1 |
| McConnell, M; Shieh, A | 1 |
| Chang, YF; Hsu, YH; Hwang, JS; Li, CC; Liang, FW; Wu, CH | 1 |
| Choi, SS; Choung, YJ; Jeong, SJ; Kim, H; Lee, CH | 1 |
| Diffenderfer, BW; Pearman, L; Pyrih, N; Wang, Y; Williams, SA | 1 |
| Gates, M; Hartling, L; Nuspl, M; Pillay, J; Vandermeer, B; Wingert, A | 1 |
| Gruntmanis, U; Riahi, S | 1 |
| Chang, YN; Chen, K; Chen, Z; Hu, F; Lei, Y; Li, H; Li, J; Liang, H; Liu, Q; Liu, S; Liu, Y; Lv, L; Wang, Y; Wang, Z; Xie, J; Xing, G; Yao, L; Yuan, H | 1 |
| Chang, YF; Cheng, TT; Huang, CF; Hwang, JS; Li, CC; Lu, TH; Shih, CA; Tai, TW; Tsai, YL; Wu, CH | 1 |
| Curraj, E; Gonzalez Rodriguez, E | 1 |
| Gong, YQ; Li, C; Lu, K; Shi, Q; Wu, YM; Zhang, T | 1 |
| Kamalanathan, S; Kar, SS; Merugu, C; Naik, D; Narayanan, N; Patel, D; Ramkumar, G; Reddy, SVB; Roy, A; Sahoo, J; Suryadevara, V | 1 |
| Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C | 1 |
| Avan, YL; Çakıroğlu, H; Çınar, BM; Keskin, D; Kochai, A; Öz, İ; Pehlivan, H | 1 |
| Ahern, E; Black, AJ; Dockery, F; Gregson, CL; Javaid, MK; Johansen, A; MacLullich, AMJ; Sahota, O | 1 |
| Kim, H; Lee, CH; Park, S; Sik Choi, S; Yoon Byun, S | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Chang, Y; Huang, S; Ke, Y; Liang, C; Liang, G; Xiao, D; Zheng, X; Zhu, X; Zhuang, J | 1 |
| Aminnejad, R; Taheri, M | 1 |
| Chen, S; Li, C; Li, H; Wang, R; Wang, Y; Yue, L | 1 |
| Ding, L; Du, H; Hu, J; Huang, H; Huang, Z; Kuang, A; Li, K; Mo, Y; Wen, F | 1 |
| Gao, Y; Hu, W; Shi, X; Song, Y; Wang, H; Xing, S; Zhang, G; Zhang, K | 1 |
| Huang, Y; Wu, D | 1 |
| Liu, SL; Luo, DM; Shen, XT; Xu, XY; Yuan, GD; Zhou, ZY | 1 |
| Kasai, H; Mori, Y; Ose, A; Shiraki, M; Tanigawara, Y | 1 |
| Aikeremu, D; Alimasi, W; Liu, Y; Lu, L; Nazierhan, S; Niyazi, W; Sun, Z; Wang, H; Xu, K | 1 |
| Li, AM; Wu, XG; Zhang, DY; Zhu, BQ | 1 |
| Bégin, MJ; Biver, E; Ferrari, S; Uebelhart, B | 1 |
| Jin, Y; Li, C; Lu, K; Shan, HQ; Yin, Y | 1 |
| Cai, B; Wang, F; Zhuang, M | 1 |
| Gong, H; Gu, J; Hao, Y; Hou, X; Li, K; Li, L; Lin, C; Wang, S; Xie, R; Yin, J; Zhang, Q | 1 |
| Ma, H; Sun, Y; Tan, M; Tang, X; Yang, F; Yi, P | 1 |
| Cromer, SJ; D'Silva, KM; Desai, RJ; Kim, SC; Landon, J; Yu, EW | 1 |
| Crandall, CJ; Fujii, T; Ganz, DA; Mori, T | 1 |
| Albert, SG; Reddy, S | 1 |
| Aeberli, D; Lehmann, T | 1 |
| Gan, F; Ge, Y; Liu, B; Yu, H | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Dai, K; Hao, Y; Li, G; Pei, J; Wang, L; Yuan, G; Zhang, L | 1 |
| Wang, H; Xiang, C; Xiao, X; Xu, W; Yuan, H; Zhao, X | 1 |
| Moser, F; Sterki Novakova, K; Tamborrini, G | 1 |
| Bersabe, D; Graybill, S; Kaufman, N; Kuiper, BW; Tate, JM | 1 |
| Beckett, T; Burkard, D; Kourtjian, E; Messingschlager, C; Padley, M; Sipahi, R; Stubbart, J | 1 |
| Balasubramanian, A; Cooper, C; Cummings, SR; Feudjo, MT; Guo, H; Sprafka, JM; Watts, NB; Yusuf, AA; Zhou, J | 1 |
| Anastasilakis, AD; Makras, P; Polyzos, SA | 1 |
| Cheng, AY; Huang, ZF; Shi, C; Zhang, M | 1 |
| Ito, K | 1 |
| Huang, ZF; Liu, K; Xiao, SX; Xiong, W | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A; Wiessing, KR | 1 |
| Cai, Q; Xu, X; Zhang, J; Zhang, T; Zhao, D | 1 |
| Brasure, M; Butler, M; Ensrud, KE; Fink, HA; Forte, ML; MacDonald, R; Nelson, VA; Olson, CM; Rosebush, CE; Schousboe, JT; Taylor, BC; Ullman, K; Wilt, TJ | 1 |
| Li, CW; Liang, BC; Liu, K; Liu, Z; Mao, YF; Shi, XL; Wu, LG | 1 |
| Arden, NK; Cooper, C; Javaid, MK; Judge, A; Lyles, KW; Prieto-Alhambra, D | 1 |
| Brance, ML; Brun, LR; Di Loreto, VE; Lupo, M; Rigalli, A | 1 |
| Agodoa, I; Kruse, M; Orwoll, E; Parthan, A; Silverman, S | 1 |
| Chen, X; Fan, L; Huang, S; Lin, H; Liu, C; Zhu, X | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Reid, IR | 1 |
| Aftring, RP; Black, DM; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Hue, TF; Lakatos, P; Leung, PC; Lippuner, K; Mukhopadhyay, A; Reid, IR; Tan, M | 1 |
| Kmietowicz, Z | 1 |
| Aslan, A; Balcı, M; Çırpar, M; Kochai, A; Tulmaç, ÖB; Türker, M | 1 |
| Fukunaga, M; Hagino, H; Ito, M; Kishimoto, H; Nakamura, T; Nakano, T; Ohashi, M; Ota, Y; Shiraki, M; Sone, T; Taguchi, A; Tanaka, S | 1 |
| He, Q; Li, Q; Li, Y; Liu, L; Pei, FX; Wang, DL; Zhao, WB | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Isaksson, H; Mathavan, N; Tägil, M | 1 |
| Bell, JM; Beringer, T; Blackwood, B; Elliott, M; Hamilton, A; Quinlivan, R; Shields, MD; Tirupathi, S; Watters, J | 1 |
| Hagino, H; Moriwaki, K; Mouri, M | 1 |
| Deas, CM; Freeman, MK; Iranikhah, M; Murphy, P | 1 |
| Kong, LC; Li, CW; Liang, BC; Shi, XL; Shi, ZY; Wang, B; Wu, P; Yao, JL | 1 |
| Bleasel, JF; Craig, SJ; Sullivan, L; Vaile, JH; Youssef, PP | 1 |
| Boonen, S; Bucci-Rechtweg, C; Cosman, F; Eriksen, EF; Gasser, JA; Guañabens, N; Kasperk, C; Miller, PD; Papanastasiou, P; Rao, H; Readie, A; Recknor, C | 1 |
| Bouler, JM; Bujoli, B; Despas, C; Fayon, F; Gauthier, O; Janvier, P; Khairoun, I; Massiot, D; Mellier, C; Montavon, G; Rouillon, T; Schnitzler, V; Walcarius, A | 1 |
| Adachi, J; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, C; Haentjens, P; Hyldstrup, L; Lyles, KW; Magaziner, J; Major, N; Mesenbrink, P; Nordsletten, L; Olson, S; Recknor, C | 1 |
| Black, DM; Bucci-Rechtweg, C; Burch, S; Palermo, L; Seeman, E; Wustrack, R | 1 |
| Feng, G; Hu, J; Li, JH; Li, YF; Luo, E; Zhou, CC; Zhu, SS | 1 |
| Dore, RK | 1 |
| Black, DM; Boonen, S; Bucci-Rechtweg, C; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Hue, TF; Lakatos, P; Leung, PC; Lippuner, K; Man, Z; Martinez, RL; Reid, IR; Ruzycky, ME; Su, G; Tan, M | 1 |
| Bilezikian, JP; Compston, JE | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Suzuki, H; Takeuchi, Y | 1 |
| Black, DM; Boonen, S; Cauley, JA; Claessens, F; Cosman, F; Eastell, R; Lyles, KW; Mesenbrink, P; Reid, IR; Su, G; Vanderschueren, D | 1 |
| Black, DM; Eastell, R; Sycheva, AV; Yang, L | 1 |
22 review(s) available for zoledronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Percutaneous Vertebroplasty Combined with Zoledronic Acid in Treatment and Prevention of Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis of Comparative Studies.
Topics: Aged; Bone Density Conservation Agents; Combined Modality Therapy; Female; Fractures, Compression; Humans; Male; Middle Aged; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Vertebroplasty; Zoledronic Acid | 2022 |
Bariatric surgery and skeletal health: A narrative review and position statement for management by the European Calcified Tissue Society (ECTS).
Topics: Bariatric Surgery; Bone Density; Bone Remodeling; Female; Gastrectomy; Gastric Bypass; Humans; Male; Obesity, Morbid; Observational Studies as Topic; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
Risk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study.
Topics: Calcium; Fractures, Compression; Humans; Kyphoplasty; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2022 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Primary Health Care; Primary Prevention; Risedronic Acid; Systematic Reviews as Topic; Zoledronic Acid | 2023 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis.
Topics: Bayes Theorem; Bone Density Conservation Agents; Cluster Analysis; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Osteoporotic Fractures; Postmenopause; Proportional Hazards Models; Risk; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2020 |
Efficacy of zoledronic acid with percutaneous kyphoplasty/vertebroplasty in the treatment of osteoporotic vertebral compression fractures: a systematic review and meta-analysis.
Topics: Combined Modality Therapy; Humans; Osteoporotic Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2020 |
[Osteoporosis: Novel drug, new recommendations].
Topics: Antibodies, Monoclonal; Bone Density; Denosumab; Drug Approval; Humans; Infusions, Parenteral; Osteoporosis; Osteoporotic Fractures; Switzerland; Zoledronic Acid | 2021 |
Effectiveness and safety of percutaneous kyphoplasty combined with zoledronic acid in treatment of osteoporotic vertebral compression fractures: a meta-analysis.
Topics: Bone Cements; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2022 |
Clinical efficacy of zoledronic acid combined with percutaneous kyphoplasty in the prevention and treatment of osteoporotic vertebral compression fracture: A systematic review and meta-analysis.
Topics: Bone Density Conservation Agents; Humans; Kyphoplasty; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2021 |
Clinical Efficacy and Safety of Zoledronic Acid Combined with PVP/PKP in the Treatment of Osteoporotic Vertebral Compression Fracture: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2021 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Teriparatide; Zoledronic Acid | 2017 |
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid | 2018 |
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Administration Schedule; Duration of Therapy; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2019 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Male; Muscular Dystrophy, Duchenne; Osteoporosis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Vibration; Vitamin D; Weight-Bearing; Zoledronic Acid | 2017 |
Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Practice Guidelines as Topic; Zoledronic Acid | 2017 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
[Combination or sequential treatment using PTH and anti-resorption therapies].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Time Factors; Zoledronic Acid | 2012 |
21 trial(s) available for zoledronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Percutaneous kyphoplasty combined with zoledronic acid for the treatment of primary osteoporotic vertebral compression fracture: a prospective, multicenter study.
Topics: Bone Cements; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Osteoporotic Fractures; Prospective Studies; Retrospective Studies; Spinal Fractures; Spine; Treatment Outcome; Zoledronic Acid | 2023 |
Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture.
Topics: Bone Density Conservation Agents; Consensus; Hip Fractures; Humans; Ireland; Osteoporotic Fractures; Zoledronic Acid | 2023 |
Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; Male; Middle Aged; Osteoporotic Fractures; Pain, Postoperative; Quality of Life; Spinal Fractures; Vertebroplasty; Zoledronic Acid | 2020 |
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Female; Humans; Lumbar Vertebrae; Male; Osteoporosis; Osteoporotic Fractures; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2021 |
Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study.
Topics: Aged; Bone Cements; Follow-Up Studies; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Prospective Studies; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2021 |
Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Aged, 80 and over; Back Pain; Bone Density Conservation Agents; Combined Modality Therapy; Female; Follow-Up Studies; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2018 |
Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open-label, long-term safety and efficacy study.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; China; Diphosphonates; Ethnicity; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2018 |
Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Prospective Studies; Zoledronic Acid | 2019 |
Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prospective Studies; Recurrence; Spinal Fractures; Thoracic Vertebrae; Zoledronic Acid | 2019 |
Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Female; Follow-Up Studies; Fracture Fixation, Intramedullary; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postoperative Care; Recurrence; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2019 |
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cognition Disorders; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2014 |
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Peptide Fragments; Procollagen; Time Factors; Zoledronic Acid | 2015 |
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Japan; Male; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2017 |
Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail anti-rotation.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Nails; Combined Modality Therapy; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Injections; Male; Middle Aged; Osteoporotic Fractures; Quality of Life; Zoledronic Acid | 2016 |
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip Joint; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Secondary Prevention; Zoledronic Acid | 2017 |
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Injections, Subcutaneous; Least-Squares Analysis; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptide Fragments; Peptides; Procollagen; Teriparatide; Zoledronic Acid | 2011 |
Association between timing of zoledronic acid infusion and hip fracture healing.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fracture Healing; Fractures, Ununited; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporotic Fractures; Postoperative Care; Postoperative Period; Radiography; Risk Factors; Zoledronic Acid | 2011 |
Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Female; Femur Neck; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prognosis; Spinal Fractures; Trauma Severity Indices; Zoledronic Acid | 2012 |
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Osteoporosis; Osteoporotic Fractures; Peptide Fragments; Procollagen; Time Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis.
Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Proportional Hazards Models; Risk; Time Factors; Zoledronic Acid | 2012 |
Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Hip Fractures; Hip Joint; Humans; Imidazoles; Middle Aged; Observer Variation; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
49 other study(ies) available for zoledronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Cost-Benefit Analysis; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Teriparatide; Zoledronic Acid | 2021 |
The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Humans; Male; Medicare; Osteoporotic Fractures; Prostatic Neoplasms, Castration-Resistant; United States; Zoledronic Acid | 2023 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates.
Topics: Bone Density Conservation Agents; Follow-Up Studies; Humans; Inpatients; Orthopedics; Osteoporosis; Osteoporotic Fractures; Secondary Prevention; Zoledronic Acid | 2022 |
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Male; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2023 |
Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; Medicare; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; United States; Zoledronic Acid | 2023 |
Letter to the Editor From Riahi and Gruntmanis: "Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates".
Topics: Humans; Inpatients; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2023 |
A Bone-Penetrating Precise Controllable Drug Release System Enables Localized Treatment of Osteoporotic Fracture Prevention via Modulating Osteoblast-Osteoclast Communication.
Topics: Animals; Bone and Bones; Drug Liberation; Female; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporotic Fractures; Rats; Zoledronic Acid | 2023 |
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
Topics: Bone Density Conservation Agents; Humans; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2023 |
[Side effects of osteoporosis treatments: how to explain them to patients?]
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid | 2023 |
The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients.
Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Humans; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Zoledronic Acid | 2023 |
Effect of a single dose of zoledronic acid on bone mineral density and trabecular bone score in Indian postmenopausal osteoporotic women with and without type 2 diabetes mellitus - A prospective cohort pilot study.
Topics: Absorptiometry, Photon; Bone Density; Cancellous Bone; Diabetes Mellitus, Type 2; Female; Humans; Lumbar Vertebrae; Osteoporotic Fractures; Pilot Projects; Postmenopause; Prospective Studies; Zoledronic Acid | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Quality-Adjusted Life Years; Teriparatide; Zoledronic Acid | 2023 |
The effect of pharmacological treatment in combination with vitamin K on healing in an experimental rat model of osteoporosis.
Topics: Animals; Bone Density Conservation Agents; Female; Fracture Healing; Osteoporosis; Osteoporotic Fractures; Rats; Rats, Sprague-Dawley; Teriparatide; Vitamin K; Zoledronic Acid | 2023 |
Risk factors for new vertebral compression fracture after vertebroplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study.
Topics: Bone Cements; Fractures, Compression; Humans; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Steroids; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2023 |
Therapeutic effect of percutaneous kyphoplasty combined with anti-osteoporosis drug on postmenopausal women with osteoporotic vertebral compression fracture and analysis of postoperative bone cement leakage risk factors: a retrospective cohort study.
Topics: Bone Cements; Bone Density Conservation Agents; Cohort Studies; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postmenopause; Postoperative Complications; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Fractures; Zoledronic Acid | 2019 |
Re: "Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures".
Topics: Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2020 |
Effects of rosuvastatin and zoledronic acid in combination on the recovery of senile osteoporotic vertebral compression fracture following percutaneous vertebroplasty.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Bone Density; Case-Control Studies; Drug Therapy, Combination; Female; Fractures, Compression; Functional Status; Humans; Male; Middle Aged; Osteoporotic Fractures; Pain Management; Pain, Postoperative; Recurrence; Retrospective Studies; Rosuvastatin Calcium; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2020 |
[Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Topics: Bone Cements; Fractures, Compression; Humans; Kyphoplasty; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Vertebroplasty; Vitamin K 2; Zoledronic Acid | 2020 |
[Treatment of severely osteoporotic vertebral compression fractures with the vertebral body stent system and percutanous kyphoplasty combined with zoledronic acid].
Topics: Aged; Aged, 80 and over; Bone Cements; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Stents; Treatment Outcome; Zoledronic Acid | 2020 |
Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Female; Fractures, Compression; Humans; Infusions, Intravenous; Interleukin-17; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Recurrence; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2020 |
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Female; Humans; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Zoledronic Acid | 2021 |
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Drug Substitution; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study.
Topics: Absorbable Implants; Alloys; Animals; Biocompatible Materials; Bone Development; Bone Nails; Bone Resorption; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Femoral Fractures; Fracture Healing; Imidazoles; Magnesium; Mesenchymal Stem Cells; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Osteoporotic Fractures; Rats, Sprague-Dawley; Zoledronic Acid | 2018 |
Topics: Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Ophthalmic Solutions; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prednisolone; Uveitis, Anterior; Zoledronic Acid | 2018 |
After the fall: improving osteoporosis treatment following hip fracture.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Denosumab; Drug Administration Schedule; Hip Fractures; Hospitalization; Humans; Osteoporosis; Osteoporotic Fractures; Quality Improvement; Retrospective Studies; Secondary Prevention; Standard of Care; Texas; Zoledronic Acid | 2018 |
Effects of bone remodeling agents following teriparatide treatment.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Femur Neck; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Teriparatide; Zoledronic Acid | 2018 |
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; United States; Zoledronic Acid | 2018 |
Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Female; Fractures, Compression; Humans; Imidazoles; Infusions, Intravenous; Kyphoplasty; Lumbar Vertebrae; Male; Osteoporotic Fractures; Radiography; Recurrence; Retrospective Studies; Spinal Fractures; Thoracic Vertebrae; Vertebroplasty; Zoledronic Acid | 2018 |
Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Homes for the Aged; Humans; Male; Markov Chains; Models, Theoretical; Nursing Homes; Osteoporosis; Osteoporotic Fractures; Outcome Assessment, Health Care; Quality of Life; Quality-Adjusted Life Years; United States; Zoledronic Acid | 2018 |
Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Cohort Studies; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporotic Fractures; Quality of Life; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2019 |
Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium, Dietary; Diphosphonates; Disease Models, Animal; Female; Fluorides; Imidazoles; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Phosphates; Rats; Rats, Sprague-Dawley; Treatment Outcome; Zoledronic Acid | 2014 |
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Male; Markov Chains; Osteoporosis; Osteoporotic Fractures; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2014 |
Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Bone Density; Bone Density Conservation Agents; Calcium; China; Cohort Studies; Comorbidity; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postural Balance; Prospective Studies; Quality of Life; Vitamin D; Zoledronic Acid | 2014 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Zoledronic acid increases bone density but does not reduce fractures in frail elderly people, study finds.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Frail Elderly; Humans; Imidazoles; Osteoporotic Fractures; Zoledronic Acid | 2015 |
Histological and biomechanical effects of zoledronate on fracture healing in an osteoporotic rat tibia model.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bony Callus; Diphosphonates; Female; Fracture Healing; Imidazoles; Osteoporosis; Osteoporotic Fractures; Rats; Rats, Wistar; Tibia; Treatment Outcome; Vitamin D; Zoledronic Acid | 2016 |
Do osteoporotic fractures constitute a greater recalcitrant challenge for skeletal regeneration? Investigating the efficacy of BMP-7 and zoledronate treatment of diaphyseal fractures in an open fracture osteoporotic rat model.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Diaphyses; Diphosphonates; Disease Models, Animal; Drug Evaluation; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Healing; Fractures, Open; Imidazoles; Osteoporotic Fractures; Ovariectomy; Radiography; Rats, Sprague-Dawley; Stress, Mechanical; X-Ray Microtomography; Zoledronic Acid | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Hip Fractures; Humans; Imidazoles; Injections, Intravenous; Japan; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Sensitivity and Specificity; Spinal Fractures; Zoledronic Acid | 2017 |
Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Zoledronic Acid | 2011 |
Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties.
Topics: Adsorption; Alendronate; Apatites; Bone Cements; Calcium Phosphates; Dielectric Spectroscopy; Diphosphonates; Hip Fractures; Imidazoles; Magnetic Resonance Spectroscopy; Osteoporotic Fractures; Time Factors; Zoledronic Acid | 2011 |
The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.
Topics: Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bony Callus; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Fracture Healing; Imidazoles; Osteoporotic Fractures; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Rats; Rats, Sprague-Dawley; Tibial Fractures; X-Ray Microtomography; Zoledronic Acid | 2012 |
Data from extension trials: denosumab and zoledronic acid.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Comorbidity; Contraindications; Creatinine; Denosumab; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; RANK Ligand; Renal Insufficiency; Treatment Outcome; Zoledronic Acid | 2012 |
Bisphosphonate therapy for osteoporosis: the long and short of it.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid | 2012 |
Zoledronic acid prevents fractures in men with osteoporosis.
Topics: Age Factors; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Incidence; Male; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid | 2012 |